Grundlæggende statistik
| CIK | 1385830 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NeurogesX, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| February 13, 2017 |
NGSX / NeurogesX, Inc. / Henriques Charles A. - FORM SC 13G/A Passive Investment Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 9, 2017 |
NGSX / NeurogesX, Inc. / KCG AMERICAS LLC - SC 13G/A NGSX 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment 2) NeurogesX, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 641252101 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 17, 2016 |
NGSX / NeurogesX, Inc. / Henriques Charles A. - FORM SC 13G/A Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* NeurogesX, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 641252 101 (CUSIP Number) January 7, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 11, 2016 |
NGSX / NeurogesX, Inc. / KCG AMERICAS LLC - SC 13G/A NGSX Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment 1) NeurogesX, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 641252101 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| January 7, 2016 |
NGSX / NeurogesX, Inc. / Henriques Charles A. - SC 13G Passive Investment SC 13G 1 schedule13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NeurogesX, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 641252 101 (CUSIP Number) January 7, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| September 18, 2015 |
NGSX / NeurogesX, Inc. / Henriques Charles A. - SC 13G/A Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 (Amendment No. )* NeurogesX, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 641252 101 (CUSIP Number) July 21, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| September 17, 2015 |
NGSX / NeurogesX, Inc. / Henriques Charles A. - SC 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NeurogesX, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 641252 101 (CUSIP Number) July 21, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 10, 2015 |
NGSX / NeurogesX, Inc. / KCG AMERICAS LLC - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Initial Filing) Under the Securities Exchange Act of 1934 NeurogesX, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 641252101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 18, 2014 |
NGSX / NeurogesX, Inc. / Arkin Moshe - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* NeurogesX, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 641252101 (CUSIP Numbe |
|
| July 11, 2013 |
8-K 1 d566855d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 July 11, 2013 (July 8, 2013) Date of Report (date of earliest event reported) NEUROGESX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33438 94-3307935 (State or other jurisdicti |
|
| June 24, 2013 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 24, 2013 (June 18, 2013) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| April 17, 2013 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 17, 2013 (April 15, 2013) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| April 1, 2013 |
NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-34372 NOTIFICATION OF LATE FILING CUSIP NUMBER 784932600 (Check One) x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11- |
|
| April 1, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 1, 2013 (March 29, 2013) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| March 27, 2013 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 27, 2013 (March 27, 2013) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| March 26, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on March 26, 2013 Post-Effective Amendment No. |
|
| March 26, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on March 26, 2013 Post-Effective Amendment No. |
|
| March 26, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on March 26, 2013 Post-Effective Amendment No. |
|
| March 26, 2013 |
s-8 POS As filed with the Securities and Exchange Commission on March 26, 2013 Post-Effective Amendment No. |
|
| March 26, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on March 26, 2013 Post-Effective Amendment No. |
|
| March 26, 2013 |
S-8 POS As filed with the Securities and Exchange Commission on March 26, 2013 Post-Effective Amendment No. |
|
| March 26, 2013 |
As filed with the Securities and Exchange Commission on March 26, 2013 Post-Effective Amendment No. |
|
| March 25, 2013 |
POS AM As filed with the Securities and Exchange Commission on March 25, 2013 Post-Effective Amendment No. |
|
| March 25, 2013 |
POS AM As filed with the Securities and Exchange Commission on March 25, 2013 Post-Effective Amendment No. |
|
| March 25, 2013 |
POS AM As filed with the Securities and Exchange Commission on March 25, 2013 Post-Effective Amendment No. |
|
| March 25, 2013 |
POS AM As filed with the Securities and Exchange Commission on March 25, 2013 Post-Effective Amendment No. |
|
| March 11, 2013 |
Entry into a Material Definitive Agreement, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 11, 2013 (March 7, 2013) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| March 5, 2013 |
Costs Associated with Exit or Disposal Activities, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 5, 2013 (February 28, 2013) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| February 14, 2013 |
NGSX / NeurogesX, Inc. / PALEFSKY HOWARD D - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* NeurogesX, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 641252101 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2013 |
NGSX / NeurogesX, Inc. / SVLSF IV, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Rule 13d-102) (Amendment No. 3) NEUROGESX, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 641252101 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 14, 2013 |
NGSX / NeurogesX, Inc. / Hercules Technology Growth Capital Inc - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 8, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 8, 2013 (January 4, 2013) NEUROGESX, INC. |
|
| November 30, 2012 |
Costs Associated with Exit or Disposal Activities, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 30, 2012 (November 29, 2012) NEUROGESX, INC. |
|
| November 14, 2012 |
NEUROGESX, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT EX-10.2 Exhibit 10.2 [***]CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. NEUROGESX, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) is mad |
|
| November 14, 2012 |
NEUROGESX, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT EX-10.1 Exhibit 10.1 [***]CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. NEUROGESX, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is mad |
|
| November 14, 2012 |
NeurogesX Reports Third Quarter 2012 Results EX-99.1 2 d441176dex991.htm PRESS RELEASE Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 NeurogesX Reports Third Quarter 2012 Results Recent Highlights: • End-of-Phase 2 FDA interaction sets guidance to enable initiation of NGX-1998 Phase 3 studies • Presented NGX-1998 Phase 2 trial data at World Congress; showed clear dose response from well-to |
|
| November 14, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2012 (November 14, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| November 14, 2012 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 14, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2012 (November 12, 2012) NEUROGESX, INC. |
|
| November 14, 2012 |
EX-10.3 EXHIBIT 10.3 MASTER SERVICE AGREEMENT This Master Service Agreement (?Agreement?) is made effective as of June 12, 2012 (the ?Effective Date?), by and between NeurogesX, Inc. located at 2215 Bridgepointe Parkway, Suite 200, San Mateo, CA 94404 (?Client?), and CoreRx, Inc. located at 6101 Johns Road, Suite 8, Tampa, Florida 33634, (?CoreRx?), as follows: 1. Definitions. 1.1. ?Applicable Law |
|
| September 14, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 14, 2012 (September 10, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| August 24, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 24, 2012 (August 23, 2012) NEUROGESX, INC. |
|
| August 10, 2012 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 10, 2012 |
SETTLEMENT, RELEASE AND PATENT ASSIGNMENT AGREEMENT EX-10.1 Exhibit 10.1 [***]CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. SETTLEMENT, RELEASE AND PATENT ASSIGNMENT AGREEMENT This Settlement, Release and Patent Assignment Agreement (this “Agreement”) is made as of April 3 |
|
| August 10, 2012 |
Exhibit 10.3 Approved as to Legal Form #1799383.7 SUBLEASE BETWEEN ORACLE AMERICA, INC. AND NEUROGESX, INC. 999 Baker Way, San Mateo, California Second (2nd) Floor SUBLEASE THIS SUBLEASE (“Sublease”) is entered into as of May 14, 2012 (the “Effective Date”), by and between ORACLE AMERICA, INC., a Delaware corporation (“Sublandlord”) and NEUROGESX, INC., a Delaware corporation (“Subtenant”), with r |
|
| August 10, 2012 |
EX-10.2 3 d366721dex102.htm EX-10.2 Exhibit 10.2 [***]CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. AMENDMENT NUMBER FOUR TO EXCLUSIVE LICENSE AGREEMENT BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AND NEUROGESX, I |
|
| August 7, 2012 |
Press Release Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] NeurogesX Provides Regulatory Update For NGX-1998 Clinical Program End-of Phase 2 FDA Guidance Supports Plan To Enter Phase 3 Development Later This Year San Mateo, Calif., (August 7, 2012) – NeurogesX, Inc. (OTCQB: NGSX; OTCBB: NGSX), a specialty pharmaceutica |
|
| August 7, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2012 (August 7, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| August 3, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 3, 2012 (August 3, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| August 3, 2012 |
NeurogesX Reports Second Quarter 2012 Results EX-99.1 2 d388601dex991.htm PRESS RELEASE Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 NeurogesX Reports Second Quarter 2012 Results Q2 2012 and Recent Highlights: • Business development process proceeding for NGX-1998 and Qutenza • End-of-Phase 2 meeting package submitted and accepted by FDA • Astellas enrolled first patient in EU clinical tr |
|
| August 2, 2012 |
Financial Statements and Exhibits, Other Events 8-K 1 d390607d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 2, 2012 (August 2, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33438 94-3307935 (State or other jurisdi |
|
| August 2, 2012 |
NeurogesX Receives Additional Notice of Allowance Covering NGX-1998 in U.S. EX-99.1 2 d390607dex991.htm PRESS RELEASE Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] NeurogesX Receives Additional Notice of Allowance Covering NGX-1998 in U.S. San Mateo, Calif., (August 2, 2012) – NeurogesX, Inc. (OTCQB: NGSX; OTCBB: NGSX), a specialty pharmaceutical company focused on developing and commercializin |
|
| June 29, 2012 |
8-K 1 d374274d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 29, 2012 (June 27, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33438 94-3307935 (State or other jurisdict |
|
| June 29, 2012 |
Trading in NeurogesX Common Stock to Move from NASDAQ to OTCBB EX-99.1 2 d374274dex991.htm PRESS RELEASE Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] Trading in NeurogesX Common Stock to Move from NASDAQ to OTCBB SAN MATEO, Calif., June 29, 2012 (GLOBE NEWSWIRE) — NeurogesX, Inc. (NASDAQ: NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfol |
|
| June 19, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 19, 2012 (June 18, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| June 19, 2012 |
NeurogesX Receives Notice of Two U.S. Patent Allowances Covering NGX-1998 EX-99.2 3 d369279dex992.htm PRESS RELEASE Exhibit 99.2 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] NeurogesX Receives Notice of Two U.S. Patent Allowances Covering NGX-1998 San Mateo, Calif., (June 19, 2012) – NeurogesX, Inc. (NASDAQ: NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio o |
|
| June 19, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 19, 2012 (June 15, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| June 19, 2012 |
NeurogesX Issued Japanese Patent for NGX-1998 Additional Japanese Patent Application Allowed EX-99.1 2 d369279dex991.htm PRESS RELEASE Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] NeurogesX Issued Japanese Patent for NGX-1998 Additional Japanese Patent Application Allowed San Mateo, Calif., (June 18, 2012) – NeurogesX, Inc. (NASDAQ: NGSX), a specialty pharmaceutical company focused on developing and commercial |
|
| June 11, 2012 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 11, 2012 (June 7, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| May 10, 2012 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 10, 2012 |
NEUROGESX, INC. EXECUTIVE EMPLOYMENT AGREEMENT Executive Employment Agreement Exhibit 10.1 NEUROGESX, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”), dated as of January 1, 2012, is entered into by and between NEUROGESX, INC., a Delaware corporation (as supplemented by Section 13 hereof, the “Company”), and RONALD A. MARTELL (the “Executive”). The Board of Directors of the Company (the “Board”) has d |
|
| May 4, 2012 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2012 (May 3, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| May 3, 2012 |
NeurogesX Reports First Quarter 2012 Results Press Release Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 NeurogesX Reports First Quarter 2012 Results Q1 2012 and Recent Highlights: • Engaged JSB-Partners, a global life sciences advisor, to assist the Company in executing its business development objectives for NGX-1998 and Qutenza® • FDA accepted the Company’s request for an End-of-Phase |
|
| May 3, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 3, 2012 (May 3, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| April 30, 2012 |
Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 27, 2012 (April 23, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| April 20, 2012 |
NeurogesX Receives Determination Letter from NASDAQ Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] NeurogesX Receives Determination Letter from NASDAQ Intends to Request Hearing to Remain Listed on NASDAQ San Mateo, Calif., (April 20, 2012) – NeurogesX, Inc. (NASDAQ: NGSX), a specialty pharmaceutical company focused on d |
|
| April 20, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 20, 2012 (April 17, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| April 19, 2012 |
NeurogesX Engages JSB-Partners to Execute Business Development Strategy EX-99.1 2 d336816dex991.htm NEUROGESX ENGAGES JSB-PARTNERS TO EXECUTE BUSINESS DEVELOPMENT STRATEGY Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] NeurogesX Engages JSB-Partners to Execute Business Development Strategy San Mateo, Calif., (April 17, 2012) – NeurogesX, Inc. (NASDAQ: NGSX), a specialty pharmaceutical compan |
|
| April 19, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 19, 2012 (April 17, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| April 12, 2012 |
Prospectus Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-180448 PROSPECTUS Common Stock This prospectus relates to the disposition from time to time of up to 2,969,685 shares of our common stock, which are held by the selling stockholders named in this prospectus. The selling stockholders acquired the common stock from us in a private placement that closed on February 3, |
|
| April 9, 2012 |
Entry into a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 9, 2012 (April 3, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| March 29, 2012 |
Form S-3 Table of Contents As filed with the U.S. Securities and Exchange Commission on March 29, 2012. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEUROGESX, INC. (Exact name of registrant as specified in its charter) Delaware 94-3307935 (State of incorporation) (I.R.S. Employer Iden |
|
| March 28, 2012 |
10-K 1 d258817d10k.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from |
|
| March 28, 2012 |
NEUROGESX, INC. INDEMNIFICATION AGREEMENT EX-10.4 3 d258817dex104.htm FORM OF INDEMNIFICATION AGREEMENT Exhibit 10.4 NEUROGESX, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is effective as of , by and between NeurogesX, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WHEREAS, the Company and Indemnitee recognize the significant cost of directors’ and officers’ liability insurance and the ge |
|
| March 28, 2012 |
NEUROGESX, INC. EXECUTIVE EMPLOYMENT AGREEMENT EX-10.13 5 d258817dex1013.htm EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.13 NEUROGESX, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”), dated as of October 27, 2011, is entered into by and between NEUROGESX, INC., a Delaware corporation (as supplemented by Section 13 hereof, the “Company”), and Stephen J. Peroutka, MD, PhD (the “Executive”). The Board of D |
|
| March 28, 2012 |
NEUROGESX, INC. AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT EX-10.9 4 d258817dex109.htm AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.9 NEUROGESX, INC. AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended & Restated Executive Employment Agreement (the “Agreement”) is made and entered into by and between Anthony DiTonno (the “Executive”) and NeurogesX, Inc., a Delaware Corporation (the “Company”), effective as of November 9, 2011 |
|
| March 28, 2012 |
EX-4.1 2 d258817dex41.htm SPECIMEN COMMON STOCK CERTIFICATE Exhibit 4.1 |
|
| March 28, 2012 |
Form S-8 As filed with the Securities and Exchange Commission on March 28, 2012 Registration No. |
|
| March 27, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 27, 2012 (March 26, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| March 27, 2012 |
FIRST AMENDMENT WARRANT AGREEMENT First Amendment to the Warrant Agreement Exhibit 4.1 FIRST AMENDMENT TO WARRANT AGREEMENT THIS FIRST AMENDMENT TO WARRANT AGREEMENT (this “Amendment”) is entered into as of March 26, 2012, by and between HERCULES TECHNOLOGY GROWTH CAPITAL, INC. (the “Warrantholder”) and NEUROGESX, INC. (the “Company”). RECITALS The Company and the Warrantholder are parties to a Warrant Agreement dated as of August |
|
| March 13, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 13, 2012 (March 7, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| March 8, 2012 |
EX-99.1 2 d312375dex991.htm PRESS RELEASE Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 NeurogesX Reports Fourth Quarter and Year-End 2011 Results Implements Restructuring to Focus on NGX-1998 Development Q4 2011 and Recent Highlights: • Positive NGX-1998 Phase 2 clinical trial in postherpetic neuralgia (PHN) patients met all study objectives • |
|
| March 8, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 8, 2012 (March 5, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| February 9, 2012 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 9, 2012 (February 9, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| February 9, 2012 |
Press Release Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] NeurogesX’ Stock Trading Halted Today FDA Advisory Committee to Review sNDA for Qutenza® (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN) San Mateo, Calif., (February 9, 2012) – NeurogesX Inc., a specialty pharmaceutical company focused on |
|
| February 9, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 9, 2012 (February 9, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| February 9, 2012 |
Press Release Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] NeurogesX Provides Update on Qutenza® (Capsaicin) 8% Patch for New Indication to Treat HIV-PN Following FDA Advisory Committee Review FDA Expected to Make Decision by March 7, 2012 San Mateo, Calif.—Feb 9, 2012— NeurogesX (NASDAQ: NGSX), a specialty pharmaceuti |
|
| February 6, 2012 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 31, 2012 by and among NeurogesX, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITAL |
|
| February 6, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 6, 2012 (January 31, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| February 6, 2012 |
Form of Registration Rights Agreement Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 31, 2012, by and among NeurogesX, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securit |
|
| February 3, 2012 |
NeurogesX Grants Equity Awards Under Its 2011 Inducement Stock Plan Press Release Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] NeurogesX Grants Equity Awards Under Its 2011 Inducement Stock Plan San Mateo, Calif., (February 3, 2012) – NeurogesX, Inc. (Nasdaq: NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain manage |
|
| February 3, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 3, 2012 (January 30, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| February 1, 2012 |
NeurogesX, Inc. Announces $3.0 Million Private Placement Press Release Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] NeurogesX, Inc. Announces $3.0 Million Private Placement San Mateo, Calif., (February 1, 2012) – NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that on Janua |
|
| February 1, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 1, 2012 (January 31, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| January 30, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2012 (January 27, 2012) NEUROGESX, INC. |
|
| January 18, 2012 |
NGSX / NeurogesX, Inc. / Arkin Moshe - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* NeurogesX, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 641252101 (CUSIP Numbe |
|
| January 6, 2012 |
SEC Response Letter [NeurogesX, Inc. Letterhead] January 6, 2012 Mellissa Campbell Duru Special Counsel Division of Corporation Finance Office of Mergers & Acquisitions United States Securities and Exchange Commission Washington, D.C. 20549-3628 Re: NeurogesX, Inc. Schedule TO-I Filed November 14, 2011 File No. 5-82872 Dear Ms. Duru: NeurogesX, Inc (the “Company”) is submitting this letter in resp |
|
| January 3, 2012 |
NeurogesX Appoints Ronald Martell President and Chief Executive Officer Press Release Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Victoria Aguiar (media) (646) 536-7013 [email protected] NeurogesX Appoints Ronald Martell President and Chief Executive Officer San Mateo, Calif., (January 3, 20 |
|
| January 3, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 3, 2012 (January 1, 2012) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| December 20, 2011 |
Amendment No. 1 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 NeurogesX, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.0001 per share (Title of Class of Securities) 6412521 |
|
| December 15, 2011 |
Exhibit 99.1 NeurogesX, Inc. The Ruth Group Stephen Ghiglieri Stephanie Carrington (investors) Executive Vice President, COO (646) 536-7017 and CFO [email protected] (650) 358-3310 [email protected] Victoria Aguiar (media) (646) 536-7013 [email protected] NeurogesX Confirms FDA Advisory Committee to Review sNDA for Qutenza? (capsaicin) 8% Patch for HIV-Associated Periphera |
|
| December 15, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2011 (December 15, 2011) NEUROGESX, INC. |
|
| November 29, 2011 |
SEC Responce Letter [NeurogesX, Inc. Letterhead] November 29, 2011 Mellissa Campbell Duru Special Counsel Division of Corporation Finance Office of Mergers & Acquisitions United States Securities and Exchange Commission Washington, D.C. 20549-3628 Re: NeurogesX, Inc. Schedule TO-I Filed November 14, 2011 File No. 5-82872 Dear Ms. Duru: NeurogesX, Inc (the “Company”) is submitting this letter in re |
|
| November 14, 2011 |
Exhibit (a)(1)(B) To: All Eligible Employees From: Tony DiTonno Re: Stock Option Exchange Offer Date: November 14, 2011 Today, we are happy to announce that we are offering you the opportunity to participate in an offer to exchange certain of your stock options for new stock options. |
|
| November 14, 2011 |
Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Victoria Aguiar (media) (646) 536-7013 [email protected] NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza? (capsaicin) 8% Patch for HIV-Associated Peripheral Ne |
|
| November 14, 2011 |
NEUROGESX, INC. AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Restated Executive Employment Agreement Exhibit 10.2 NEUROGESX, INC. AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended & Restated Executive Employment Agreement (the “Agreement”) is made and entered into by and between Stephen Ghiglieri (the “Executive”) and NeurogesX, Inc., a Delaware Corporation (the “Company”), effective as of September 19, 2011 (the “Effective Date”). RECITALS WHE |
|
| November 14, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2011 (November 14, 2011) NEUROGESX, INC. |
|
| November 14, 2011 |
NEUROGESX, INC. ELECTION AND WITHDRAWAL FORM Exhibit (a)(1)(C) NEUROGESX, INC. ELECTION AND WITHDRAWAL FORM Please review, complete and sign this form, then either (1) fax it to Michelle Evans at 650-523-4312 or (2) e-mail (via PDF or similar imaged document file) it to [email protected] before 9:00 p.m., Pacific Time, on December 12, 2011. DELIVERY OF YOUR ELECTION AND WITHDRAWAL FORM OTHER THAN BY FAX OR E-MAIL, OR TO A NUMBER O |
|
| November 14, 2011 |
NEUROGESX, INC. CONSULTING AGREEMENT EX-10.5 5 d235134dex105.htm CONSULTING AGREEMENT Exhibit 10.5 NEUROGESX, INC. CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is entered into as of September 27, 2011 by and between NeurogesX, Inc., a Delaware corporation (the “Company”), and Jeffrey Tobias, M.D., as of October 16, 2011, a former employee and executive of the Company (“Consultant”). The Company desires to retain |
|
| November 14, 2011 |
NEUROGESX, INC. 2007 STOCK PLAN NOTICE OF GRANT OF STOCK OPTION Exhibit (a)(1)(G) NEUROGESX, INC. 2007 STOCK PLAN NOTICE OF GRANT OF STOCK OPTION Unless otherwise defined herein, the terms defined in the 2007 Stock Plan, as amended, (the ?Plan?) will have the same defined meanings in this Notice of Grant of Stock Option (the ?Notice of Grant?) and Terms and Conditions of Stock Option Grant, attached hereto as Exhibit A (together, the ?Agreement?). Participant: |
|
| November 14, 2011 |
NEUROGESX, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Restated Executive Employment Agreement Exhibit 10.3 NEUROGESX, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is made and entered into by and between Jeffrey Tobias (the “Executive”) and NeurogesX, Inc., a Delaware Corporation (the “Company”), effective as of September 19, 2011 (the “Effective Date”). RECITALS WH |
|
| November 14, 2011 |
Tender Offer UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 NeurogesX, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.0001 per share (Title of Class of Securities) 641252101 (CUSIP Number of Class of Securiti |
|
| November 14, 2011 |
NEUROGESX, INC. 2000 STOCK INCENTIVE PLAN STOCK OPTION AGREEMENT Exhibit (a)(1)(F) NEUROGESX, INC. 2000 STOCK INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2000 Stock Incentive Plan shall have the same defined meanings in this Stock Option Agreement. I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned Optionee has been granted an Option to purchase Common Stock of the Company, subject to the terms and |
|
| November 14, 2011 |
Exhibit (a)(1)(E) Forms of Reminder and Last Day E-mails To: All Eligible Employees Subject: NeurogesX? Exchange Offer Closes Soon A letter was sent to you on November 14, 2011, from Tony DiTonno that provided you with instructions about how to participate in the NeurogesX Offer to Exchange Certain Stock Options for New Stock Options. |
|
| November 14, 2011 |
As filed with the Securities and Exchange Commission on November 14, 2011 Form S-8 As filed with the Securities and Exchange Commission on November 14, 2011 Registration No. |
|
| November 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33438 NEUROGESX, INC. (Exac |
|
| November 14, 2011 |
Exhibit (a)(1)(D) Confirmation E-mail or Letter to Employees who Elect to Participate in the Offer to Exchange Certain Stock Options for New Stock Options To: [NAME] Subject: Confirmation of Election Dear [NAME]: This message confirms that NeurogesX has received your election to participate in the Exchange Offer. |
|
| November 14, 2011 |
Offer to Exchange Certain Stock Options for New Stock Options Exhibit (a)(1)(A) NeurogesX, Inc November 14, 2011 OFFER TO EXCHANGE CERTAIN STOCK OPTIONS FOR NEW STOCK OPTIONS This offer to exchange and your withdrawal rights will expire at 9:00 p. |
|
| November 14, 2011 |
NEUROGESX, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.4 NEUROGESX, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) is made and entered into by and between Michael Markels (the ?Executive?) and NeurogesX, Inc., a Delaware Corporation (the ?Company?), effective as of September 19, 2011 (the ?Effective Date?). RECITALS WHEREAS, the Company and Executive entere |
|
| November 10, 2011 |
Exhibit 24 POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of NeurogesX, Inc. |
|
| November 8, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2011 (November 8, 2011) NEUROGESX, INC. |
|
| November 8, 2011 |
1 NGX-1998 Phase 2 (C204 Study) Postherpetic Neuralgia (PHN) Top-Line Results November 8, 2011 Exhibit 99. |
|
| November 8, 2011 |
Exhibit 99.1 NeurogesX Reports Positive Phase 2 Results for NGX-1998 for Treatment of Postherpetic Neuralgia Study Results Support 5 Minute Application of Topical Liquid Capsaicin Formulation Conference Call Today at 8:30am (ET) San Mateo, Calif., November 8, 2011 ? NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies |
|
| October 31, 2011 |
NeurogesX Appoints Dr. Stephen J. Peroutka as Executive Vice President and Chief Medical Officer Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Victoria Aguiar (media) (646) 536-7013 [email protected] NeurogesX Appoints Dr. Stephen J. Peroutka as Executive Vice President and Chief Medical Officer San Mateo, Calif., (Oc |
|
| October 31, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 31, 2011 (October 31, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| October 31, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 31, 2011 (October 27, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| October 31, 2011 |
Press Release Exhibit 99.1 NeurogesX, Inc. The Ruth Group Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 Stephanie Carrington (investors) (646) 536-7017 [email protected] Victoria Aguiar (media) (646) 536-7013 [email protected] NeurogesX Reports Third Quarter 2011 Results Announces Operational Restructure Conference Call Today at 4:30pm EDT Recent Highligh |
|
| October 31, 2011 |
SCHEDULE TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE TO (Rule 13e-4) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 NEUROGESX, INC. |
|
| October 31, 2011 |
Script of October 31, 2011 Teleconference Exhibit 99.2 NeurogesX, Inc. Third Quarter 2011 Conference Call October 31, 2011 Operator: Greetings ladies and gentlemen and welcome to the NeurogesX Inc.’s Third Quarter 2011 conference call to discuss the quarterly results and provide a business update. At this time, all participants are in a listen-only mode. A brief question and answer session will fo |
|
| October 31, 2011 |
Exhibit 99.1 NeurogesX, Inc. Third Quarter 2011 Conference Call October 31, 2011 Operator: Greetings ladies and gentlemen and welcome to the NeurogesX Inc.?s Third Quarter 2011 conference call to discuss the quarterly results and provide a business update. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone sh |
|
| October 21, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 18, 2011 (October 21, 2011) NEUROGESX, INC. |
|
| September 27, 2011 |
Press Release Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Victoria Aguiar (media) (646) 536-7013 [email protected] NeurogesX Announces Resignation of EVP of Research and Development and Chief Medical Officer Jeffrey K To |
|
| September 27, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 27, 2011 (September 21, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| September 26, 2011 |
NEUROGESX, INC. 2011 INDUCEMENT STOCK PLAN Exhibit 10.1 NEUROGESX, INC. 2011 INDUCEMENT STOCK PLAN 1. Purposes of the Plan. The purposes of this Plan are to provide a material inducement for the best available individuals to enter into the employment of the Company and thereby to promote the success of the Company’s business. The Plan shall be used exclusively for “employment inducement grants” within the meaning of The NASDAQ Stock Market |
|
| September 26, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 26, 2011 (September 20, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| September 8, 2011 |
Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 [email protected] The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Victoria Aguiar (media) (646) 536-7013 [email protected] NeurogesX Submits Supplemental New Drug Application for Qutenza? (capsaicin) 8% Patch for HIV-Associated Peripheral Neu |
|
| September 8, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 8, 2011 (September 8, 2011) NEUROGESX, INC. |
|
| September 8, 2011 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-176471 PROSPECTUS Common Stock This prospectus relates to the disposition from time to time of up to 17,624,334 shares of our common stock, which includes 5,874,782 shares of our common stock issuable upon the exercise of warrants, which are held by the selling stockholders named in this prospectus. The selling stockholders ac |
|
| September 1, 2011 |
POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of NeurogesX, Inc. |
|
| August 24, 2011 |
As filed with the U.S. Securities and Exchange Commission on August 24, 2011. Table of Contents As filed with the U.S. Securities and Exchange Commission on August 24, 2011. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEUROGESX, INC. (Exact name of registrant as specified in its charter) Delaware 94-3307935 (State of incorporation) (I.R.S. Employer Identificati |
|
| August 24, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2*)** NeurogesX, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 641252101 (CUSIP Num |
|
| August 22, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NeurogesX, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 641252101 (CUSIP Number) July 26, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| August 17, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* NeurogesX, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 641252101 (CUSIP Numbe |
|
| August 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33438 |
|
| August 9, 2011 |
Exhibit 4.1 THIS WARRANT, AND ANY SECURITIES ISSUED PURSUANT TO THIS WARRANT, HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SEC |
|
| August 9, 2011 |
Script of Teleconference Exhibit 99.2 NeurogesX, Inc. Second Quarter 2011 Conference Call August 9, 2011 Operator: Greetings ladies and gentlemen and welcome to the NeurogesX Inc.’s Second Quarter 2011 conference call to discuss the quarterly results and our Qutenza launch metrics. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal |
|
| August 9, 2011 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2011 (August 9, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| August 9, 2011 |
NeurogesX Reports Second Quarter 2011 Results Conference Call Today at 8:30am EDT PRESS RELEASE Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Victoria Aguiar (media) (646) 536-7013 [email protected] NeurogesX Reports Second Quarter 2011 Results Conference Call Today at 8:30am EDT Recent Highlights: • Completed equity and debt f |
|
| August 9, 2011 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of August 5, 2011 and is entered into by and between NEUROGESX, INC., a Delaware corporation (hereinafter referred to as the “Borrower”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”). RECITALS A. Borrower has requested Lender to make available to Borrower a term loan in |
|
| August 9, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2011 (August 05, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| August 8, 2011 |
NeurogesX, Inc. Secures $20 Million Debt Facility Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Victoria Aguiar (media) (646) 536-7013 [email protected] NeurogesX, Inc. Secures $20 Million Debt Facility San Mateo, Calif., August 8, 2011 – NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical compan |
|
| August 8, 2011 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2011 (August 8, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| August 4, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* NeurogesX, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 641252101 (CUSIP Number) Mark McDonnell ARCH Venture Corporation 8725 W. Higgins Road Suite 290 Chicago, IL 60631 (Name, Address and Telephone Number of Person |
|
| July 27, 2011 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 21, 2011 by and among NeurogesX, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). RECITALS A. The Company and each Purchaser is ex |
|
| July 27, 2011 |
Form of Registration Rights Agreement Exhibit 4.1 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 21, 2011, by and among NeurogesX, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant |
|
| July 27, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 27, 2011 (July 21, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| July 27, 2011 |
NEUROGESX, INC. WARRANT TO PURCHASE COMMON STOCK Exhibit 4.2 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIE |
|
| July 25, 2011 |
POWERS OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark McDonnell his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a |
|
| July 22, 2011 |
Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Victoria Aguiar (media) (646) 536-7013 [email protected] NeurogesX, Inc. Announces $20 Million Private Placement San Mateo, Calif., July 22, 2011 ? NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical c |
|
| July 22, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 22, 2011 (July 22, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| June 30, 2011 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| June 16, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 16, 2011 (June 16, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| June 16, 2011 |
NeurogesX Completes Phase 2 Enrollment of NGX-1998 Topical Liquid Capsaicin Formulation Trial Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Jason Rando (media) (646) 536-7025 [email protected] NeurogesX Completes Phase 2 Enrollment of NGX-1998 Topical Liquid Capsaicin Formulation Trial San Mateo, Calif., (June 16, 2011) ? NeurogesX, Inc. (N |
|
| June 6, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 6, 2011 (June 2, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| June 6, 2011 |
POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of NeurogesX, Inc. |
|
| May 9, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 d10q.htm QUARTERLY REPORT ON FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission fi |
|
| April 29, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 29, 2011 (April 29, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| April 29, 2011 |
NEUROGESX, INC. RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Restated Executive Employment Agreement - Jeffrey Tobias Exhibit 10.3 NEUROGESX, INC. RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Restated Executive Employment Agreement (the “Agreement”) is made and entered into by and between Jeffrey Tobias (the “Executive”) and NeurogesX, Inc., a Delaware Corporation (the “Company”), effective as of April 26, 2011 (the “Effective Date”). RECITALS WHEREAS, the |
|
| April 29, 2011 |
NEUROGESX, INC. RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Restated Executive Employment Agreement - Stephen Ghiglieri Exhibit 10.2 NEUROGESX, INC. RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Restated Executive Employment Agreement (the “Agreement”) is made and entered into by and between Stephen Ghiglieri (the “Executive”) and NeurogesX, Inc., a Delaware Corporation (the “Company”), effective as of April 26, 2011 (the “Effective Date”). RECITALS WHEREAS |
|
| April 29, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2011 (April 27, 2011) NEUROGESX, INC. |
|
| April 29, 2011 |
Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Jason Rando (media) (646) 536-7025 [email protected] NeurogesX CEO Anthony DiTonno to Retire by Year End -Gary Lyons Joins Board as Executive Chairman- -Jean-Jacques Bienaim? Moves to Lead Independent D |
|
| April 29, 2011 |
NEUROGESX, INC. RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 NEUROGESX, INC. RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Restated Executive Employment Agreement (the “Agreement”) is made and entered into by and between Anthony DiTonno (the “Executive”) and NeurogesX, Inc., a Delaware Corporation (the “Company”), effective as of April 26, 2011 (the “Effective Date”). RECITALS WHEREAS, the Company and Executive entered into an employment agreeme |
|
| April 29, 2011 |
Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Jason Rando (media) (646) 536-7025 [email protected] NeurogesX Reports First Quarter 2011 Results - Investor Day Today at 8:15 am EDT to Highlight Launch Metrics - First Quarter 2011 Highlights: ? Quten |
|
| April 29, 2011 |
NEUROGESX, INC. RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.4 NEUROGESX, INC. RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Restated Executive Employment Agreement (the ?Agreement?) is made and entered into by and between Michael Markels (the ?Executive?) and NeurogesX, Inc., a Delaware Corporation (the ?Company?), effective as of April 26, 2011 (the ?Effective Date?). RECITALS WHEREAS, the Company and Executive entered into an employment agreeme |
|
| April 29, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2011 (April 26, 2011) NEUROGESX, INC. |
|
| April 28, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 28, 2011 (April 28, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| April 28, 2011 |
Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Jason Rando (media) (646) 536-7025 [email protected] NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid Provides update on other recent patent issuances San Mat |
|
| April 26, 2011 |
Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 25, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 25, 2011 (April 21, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| April 25, 2011 |
EX-99.1 2 dex991.htm PRESS RELEASE Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Jason Rando (media) (646) 536-7025 [email protected] NeurogesX to Host Investor Day on April 29 - Review of First Quarter 2011 Results - - Update of Qutenza Launch - S |
|
| March 31, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* NeurogesX, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 641252101 (CUSIP Number |
|
| March 31, 2011 |
EXHIBIT 1 JOINT FILING AGREEMENT By this Agreement, the undersigned agree that this Statement on Schedule 13G being filed on or about this date, and any subsequent amendments thereto filed by any of us, with respect to the securities of NeurogesX, Inc. |
|
| March 31, 2011 |
EX-99 4 exhibit3.htm EXHIBIT 3 EXHIBIT 3 Special Power of Attorney The undersigned, as Chairman of M. Arkin (1999) Ltd., does hereby make, constitute and appoint Menachem Inbar as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to: (1) prepare, execute, acknowledge, deliver a |
|
| March 31, 2011 |
EXHIBIT 4 SPHERA FUNDS MANAGEMENT LTD. (the ?Company?) UNANIMOUS WRITTEN RESOLUTIONS OF THE DIRECTORS OF THE COMPANY DATED 1ST JULY, 2010 The undersigned, comprising all the members of the Board of Directors of the Company, in lieu of meeting, pursuant to the Articles of Association of the Company and waiving any prior notice requirements, do hereby consent in writing as follows: It is hereby RESO |
|
| March 31, 2011 |
EXHIBIT 2 Special Power of Attorney The undersigned does hereby make, constitute and appoint Menachem Inbar as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to: (1) prepare, execute, acknowledge, deliver and file Schedule 13D (including any amendments thereto) or Schedule 13G (including any amendments thereto) with respect to the securities of NeurogesX, Inc. |
|
| March 30, 2011 |
NeurogesX Reports Fourth Quarter and Year-End 2010 Results Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Stephanie Carrington (investors) (646) 536-7017 [email protected] Jason Rando (media) (646) 536-7025 [email protected] NeurogesX Reports Fourth Quarter and Year-End 2010 Results Recent Highlights: • Qutenza® (capsaicin) 8% patch launch in US by NeurogesX sales force d |
|
| March 30, 2011 |
As filed with the Securities and Exchange Commission on March 30, 2011 As filed with the Securities and Exchange Commission on March 30, 2011 Registration No. |
|
| March 30, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 30, 2011 (March 30, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| March 30, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33 |
|
| February 17, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Rule 13d-102) (Amendment No. 2) NEUROGESX, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 641252101 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 14, 2011 |
Exhibit 99.1 NeurogesX, Inc. Fourth Quarter 2010 Conference Call to Discuss Launch Metrics February 14, 2010 Operator: Greetings ladies and gentlemen and welcome to the NeurogesX Inc. Fourth Quarter 2010 conference call to discuss Launch Metrics. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should requi |
|
| February 14, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 14, 2011 (February 14, 2011) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| February 9, 2011 |
Amendment No. 1 to Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 9, 2011 (November 17, 2010) NEUROGESX, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33438 94-3307935 |
|
| February 9, 2011 |
Current Report on Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 9, 2011 (February 3, 2011) NEUROGESX, INC. |
|
| January 21, 2011 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| December 2, 2010 |
Response Letter December 2, 2010 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assitant Director Jim B. Rosenberg, Senior Assistant Chief Accountant Sasha Parikh, Staff Accountant Mark Brunhofer, Review Accountant Michael Rosenthall Re: NeurogesX, Inc. Form 10-K for the Fiscal Year En |
|
| November 22, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 22, 2010 (November 17, 2010) NEUROGESX, INC. |
|
| November 9, 2010 |
As filed with the Securities and Exchange Commission on November 9, 2010 Form S-8 As filed with the Securities and Exchange Commission on November 9, 2010 Registration No. |
|
| November 8, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 3, 2010 |
Exhibit 99.2 NeurogesX, Inc. Third Quarter 2010 Conference Call November 3, 2010 Operator: Greetings ladies and gentlemen and welcome to the NeurogesX Inc. third Quarter 2010 conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please pr |
|
| November 3, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2010 (November 2, 2010) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| November 3, 2010 |
Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Sara Pellegrino (investors) (646) 536-7002 [email protected] Jason Rando (media) (646) 536-7025 [email protected] NeurogesX Reports Third Quarter 2010 Results Conference Call Today at 8:30am ET to Highlight Key Launch Metrics Recent Highlights: • Qutenza user base exp |
|
| November 3, 2010 |
NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation Press Release Exhibit 99.3 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Sara Pellegrino (investors) (646) 536-7002 [email protected] Jason Rando (media) (646) 536-7025 [email protected] NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation San Mateo, Calif., (November 2, 2010) – Neu |
|
| October 15, 2010 |
[NeurogesX letterhead] October 15, 2010 Correspondence Letter [NeurogesX letterhead] October 15, 2010 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Jim B. Rosenberg, Senior Assistant Chief Accountant Sasha Parikh, Staff Accountant Mark Brunhofer, Review Accountant Michael Rosenthall Re: NeurogesX, Inc. Fo |
|
| October 12, 2010 |
[NeurogesX Letterhead] October 12, 2010 [NeurogesX Letterhead] October 12, 2010 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assitant Director Jim B. Rosenberg, Senior Assistant Chief Accountant Sasha Parikh, Staff Accountant Mark Brunhofer, Review Accountant Michael Rosenthall Re: NeurogesX, Inc. Form 10-K for t |
|
| September 28, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 28, 2010 (September 23, 2010) NEUROGESX, INC. |
|
| August 12, 2010 |
As filed with the Securities and Exchange Commission on August 12, 2010 Table of Contents As filed with the Securities and Exchange Commission on August 12, 2010 Registration No. |
|
| August 12, 2010 |
EXHIBIT 4.3 NEUROGESX, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions 1 Section 1.2 Compliance Certificates and Opinions 10 Section 1.3 Form of Documents Delivered to Trustee 11 Section 1.4 Acts of Holders; Record Dates 11 Section 1.5 Notices, etc., to Trus |
|
| August 12, 2010 |
EXHIBIT 4.2 NEUROGESX, INC, TO AS TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions 1 Section 1.2 Compliance Certificates and Opinions 9 Section 1.3 Form of Documents Delivered to Trustee 9 Section 1.4 Acts of Holders; Record Dates 10 Section 1.5 Notices, etc., to Trustee and |
|
| August 12, 2010 |
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES Exhibit 12.1 COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES Our earnings were insufficient to cover fixed charges for each of the periods presented. Accordingly, the following table sets forth the deficiency of earnings to fixed charges for each of the periods presented. Because of the deficiency, ratio information is not applicable. Computation of Earnings to Fixed Charges (In thousands) Year |
|
| August 11, 2010 |
AMENDMENT TO FINANCING AGREEMENT Exhibit 10.3 AMENDMENT TO FINANCING AGREEMENT THIS AMENDMENT, dated May 20, 2010 (this “Amendment”), to the Financing Agreement made the 29th day of April, 2010 (the “Financing Agreement”) between NeurogesX, Inc., a Delaware corporation (“NeurogesX”) and Cowen Healthcare Royalty Partners, L.P., a limited partnership organized under the laws of the state of Delaware (“CHRP”, and together with Neuro |
|
| August 11, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 11, 2010 |
Financing Agreement - Cowen Healthcare Royalty Partners, L.P. Exhibit 10.2 [***]CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXECUTION COPY FINANCING AGREEMENT Dated as of April 29, 2010 between NEUROGESX, INC. and COWEN |
|
| August 11, 2010 |
2010 Executive Bonus Plan NeurogesX Executive Bonus Plan – 2010 Exhibit 10.1 2010 Executive Bonus Plan NeurogesX Executive Bonus Plan – 2010 ELIGIBILITY All Full-Time Regular and Part-Time Regular (minimum 30 hours per week during the Bonus Plan period) Executives hired prior to October 1, 2010 except for those Executives eligible under a separate incentive based compensation plan, such as the Incentive Compensation Plan. Executives hired between January 1, 20 |
|
| August 10, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2010 (August 5, 2010) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| August 10, 2010 |
AMENDMENT NO. 2 TO THE THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 10.1 AMENDMENT NO. 2 TO THE THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This AMENDMENT NO. 2 TO THE THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is dated as of August 5, 2010 (this “Amendment”) and is entered into by and among NeurogesX, Inc., a Delaware corporation (the “Company”), the parties defined as “Investors” in the IRA (as defined below) (each a “Prior Investo |
|
| August 5, 2010 |
NeurogesX Reports Second Quarter 2010 Results Conference Call Today at 4:30pm ET Press Release Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Sara Pellegrino (investors) (646) 536-7002 [email protected] Jason Rando (media) (646) 536-7025 [email protected] NeurogesX Reports Second Quarter 2010 Results Conference Call Today at 4:30pm ET Recent Highlights: • Qutenza launched in April, 2010 • Qute |
|
| August 5, 2010 |
Exhibit 99.2 NeurogesX, Inc. Second Quarter 2010 Conference Call August 5, 2010 Operator: Greetings ladies and gentlemen and welcome to the NeurogesX Inc. second Quarter 2010 conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please pr |
|
| August 5, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 5, 2010 (August 5, 2010) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| August 5, 2010 |
NeurogesX Announces Proposed Shelf Registration Statement Exhibit 99.3 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Sara Pellegrino (investors) (646) 536-7002 [email protected] Jason Rando (media) (646) 536-7025 [email protected] NeurogesX Announces Proposed Shelf Registration Statement San Mateo, Calif., (August 5, 2010) – NeurogesX, Inc. (Nasdaq: NGSX) announced today that on or |
|
| July 29, 2010 |
Press Release Exhibit 99.1 PRESS RELEASE NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Sara Pellegrino (investors) (646) 536-7002 [email protected] Jason Rando (media) (646) 536-7025 [email protected] NeurogesX Progresses on Coverage for Qutenza® Medicare Part B Coverage Confirmed Nationwide CMS Issued Temporary C-Code Specif |
|
| July 29, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2010 (July 27, 2010) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| July 29, 2010 |
Form 3 EXHIBIT 24.1 CONFIRMING STATEMENT This statement confirms that the undersigned, as Chairman of M. Arkin (1999) Ltd. (the "Reporting Person"), has authorized and designated Menachem Inbar, or a designee whom he may select from time to time (the "Agents"), acting individually, to execute, sign and file on the Reporting Person's behalf the Form ID and all Forms 3, 4 and 5, including any amendm |
|
| July 29, 2010 |
Moshe Arkin EXHIBIT 24.2 CONFIRMING STATEMENT This statement confirms that the undersigned, or the Reporting Person, Moshe Arkin, has authorized and designated Menachem Inbar, or a designee whom he may select from time to time (the "Agents"), acting individually, to execute, sign and file on the Reporting Person's behalf the Form ID and all Forms 3, 4 and 5, including any amendments thereto, that |
|
| June 7, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 7, 2010 (June 2, 2010) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| June 7, 2010 |
NEUROGESX, INC. 2007 STOCK PLAN (As Amended and Restated June 2, 2010) 2007 Stock Plan (as amended) Exhibit 99.1 NEUROGESX, INC. 2007 STOCK PLAN (As Amended and Restated June 2, 2010) 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. Th |
|
| May 13, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 13, 2010 |
2010 Executive Bonus Plan NeurogesX Executive Bonus Plan – 2010 Exhibit 10.1 2010 Executive Bonus Plan NeurogesX Executive Bonus Plan – 2010 ELIGIBILITY All Full-Time Regular and Part-Time Regular (minimum 30 hours per week during the Bonus Plan period) Executives hired prior to October 1, 2010 except for those Executives eligible under a separate incentive based compensation plan such as the Incentive Compensation Plan. Executives hired between January 1, 201 |
|
| May 11, 2010 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2010 Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| May 11, 2010 |
NeurogesX Reports First Quarter 2010 Results Conference Call Today at 4:30pm ET Exhibit 99.1 NeurogesX, Inc. The Ruth Group Stephen Ghiglieri Sara Pellegrino (investors) Executive Vice President, COO (646) 536-7002 and CFO [email protected] (650) 358-3310 Jason Rando (media) (646) 536-7025 [email protected] NeurogesX Reports First Quarter 2010 Results Conference Call Today at 4:30pm ET Recent Highlights: • NeurogesX sales force launched Qutenza® (capsaicin) 8 |
|
| May 11, 2010 |
Exhibit 99.2 NeurogesX, Inc. First Quarter 2010 Conference Call May 11, 2010 Operator: Greetings ladies and gentlemen and welcome to the NeurogesX Inc. First Quarter 2010 conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press |
|
| May 6, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2010 (April 30, 2010) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| May 6, 2010 |
NeurogesX Enters $40 Million Royalty Financing Agreement with Cowen Healthcare Royalty Partners Exhibit 99.1 NeurogesX, Inc. The Ruth Group Stephen Ghiglieri Sara Pellegrino (investors) Executive Vice President, COO (646) 536-7002 and CFO [email protected] (650) 358-3310 Jason Rando (media) (646) 536-7025 [email protected] NeurogesX Enters $40 Million Royalty Financing Agreement with Cowen Healthcare Royalty Partners San Mateo, Calif., (April 30, 2010) ? NeurogesX, Inc. (NAS |
|
| May 3, 2010 |
SCHEDULE 14A (RULE 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. |
|
| April 20, 2010 |
Definitive Proxy Statement SCHEDULE 14A (RULE 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. |
|
| April 6, 2010 |
Press Release Exhibit 99.1 FOR IMMEDIATE RELEASE NeurogesX, Inc. Anthony DiTonno President and Chief Executive Officer 650-358-3330 Media Contact Amy Losak Ketchum 646-935-3917, [email protected] Qutenza® (capsaicin) 8% Patch for Treatment of Post-Shingles Pain Now Available A single one-hour Qutenza localized treatment can provide three months relief from pain associated with postherpetic neu |
|
| April 6, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 6, 2010 (April 5, 2010) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| March 30, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 30, 2010 (March 24, 2010) Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| March 29, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* NeurogesX, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 641252101 (CUSIP Number) December 29, |
|
| March 19, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33 |
|
| March 18, 2010 |
EX-99.2 3 dex992.htm SCRIPT OF MARCH 18, 2010 TELECONFERENCE Exhibit 99.2 NeurogesX, Inc. 2009 Year End Earnings Conference Call March 18, 2010 Operator: Greetings ladies and gentlemen and welcome to the NeurogesX Inc. Fourth Quarter and Year End 2009 earnings call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If |
|
| March 18, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 18, 2010 Date of Report (date of earliest event reported) NEUROGESX, INC. |
|
| March 18, 2010 |
Press Release Exhibit 99.1 NeurogesX, Inc. Stephen Ghiglieri Executive Vice President, COO and CFO (650) 358-3310 The Ruth Group Sara Pellegrino (investors) (646) 536-7002 [email protected] Jason Rando (media) (646) 536-7025 [email protected] NeurogesX Reports Fourth Quarter and Year-End 2009 Results U.S. Sales Force to Launch Qutenza in April 2010 Qutenza U.S. Price Established 2 |
|
| February 22, 2010 |
SC 13D EXHIBIT 1 JOINT FILING AGREEMENT By this Agreement, the undersigned agree that this Statement on Schedule 13D being filed on or about this date, and any subsequent amendments thereto filed by any of us, with respect to the securities of NeurogesX, Inc. |
|
| February 22, 2010 |
SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(A) AND AMENDMENTS THERETO FILED PURSUANT TO RULED 13D-2(A) UNDER THE SECURITIES ACT OF 1934 NEUROGESX, INC. (Name of Issuer) Common Stock 641252101 (Title of class of securities) (CUSIP number) Moshe Arkin 6 Hachoshlim Street Herzelia 467 |
|
| February 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Rule 13d-102) (Amendment No. 1) NEUROGESX, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 641252101 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 16, 2010 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1(B), (C), AND (D) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2)* NeurogesX, Inc. - (NAME OF ISSUER) Common Stock - (TITLE OF CLASS OF SECURITIES) 641252101 |
|
| February 16, 2010 |
SC 13G/A EXHIBIT 1 JOINT FILING AGREEMENT By this Agreement, the undersigned agree that this Statement on Schedule 13G being filed on or about this date, and any subsequent amendments thereto filed by any of us, with respect to the securities of NeurogesX, Inc. |
|
| February 12, 2010 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
